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Abstract: Mn(II), Co(II), Ni(II), Cu(II), and Zn(II) transition metal complexes of 2-hydroxy-5-[(E)-(4-phenyl) diazenyl]
benzaldehyde oxime and 2-hydroxy-5-[(E)-(4-nitrophenyl) diazenyl] benzaldehyde oxime ligands were synthesized and
characterized through NMR, IR, ESI mass, and UV analysis. DNA binding abilities of the complexes were revealed
using a UV-Vis spectrophotometer with the absorption titration and competitive binding techniques. Hydrolytic and
oxidative DNA cleavage activities under diﬀerent conditions were also proved. Topoisomerase I inhibition eﬃciencies
and in vitro free radical scavenging activities of all complexes were examined. Finally, the selective cytotoxic potentials
of all complexes were evaluated in human colon cancer, normal colon, and fibroblast cell lines using the water-soluble
tetrazolium salt (WST-1) assay. The complexes had the ability to intercalate into stacked base pairs of DNA and
topoisomerase I activity was reasonably inhibited in their presence in 0.4 mM concentrations. The abilities for scavenging
of DPPH and hydroxyl radicals were found to be higher than those of known standard antioxidants (ascorbic acid,
butylated hydroxyanisole, and mannitol). The results obtained from the cytotoxicity experiments are especially promising
for further research, which must be carried out for the evaluation of the studied complexes as anticancer drugs.
Key words: Antioxidant activity, bioinorganic chemistry, cytotoxic activity, DNA binding and cleavage activity,
topoisomerase inhibitor, transition metal compounds

1. Introduction
Cancer treatment is based inter alia on preventing the proliferation of cancer cells by blocking DNA replication. 1
Therefore, DNA is the primary target for many anticancer drugs. 2 This is also true for metal-containing drugs
because of the metal-binding sites on DNA. 3 The pharmacological activities of complexes depend on the type
of metal ion and ligands. 4 Therefore, complexes synthesized from the same ligands with diﬀerent metal ions
have diﬀerent biological properties. 5 In the present study the drug eﬃciencies of the transition metal complexes
of two diﬀerent oxime ligands were evaluated as a result of their interactions with DNA. Oximes are widely
identified ligands and the potential applications of their metal complexes are of great interest to scientists. 6
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Briefly, metallodrugs containing oxime ligands are widely utilized in drug discovery 7 to overcome the side eﬀects
of platinum-based drugs. 8 Transition metal complexes showing pharmaceutical activity through interaction with
DNA are bound to DNA either covalently or noncovalently. Intercalation, which is related to the antitumor
activity of the compound, is one of the most important DNA binding modes 9 and occurs by the insertion of
a planar molecule between DNA base pairs. As a result of intercalation, cellular degradation begins with the
decrease in the DNA helical twist and lengthening of the DNA. 10 Moreover, redox active coordination complexes
induce DNA cleavages depending on the type of metal ion, which plays a critical role. Complexes having such
a capability are useful tools in molecular biology and medicine. 11 The topoisomerase inhibition eﬃciency of
a complex also contributes to its evaluation as an anticancer agent because DNA topoisomerases are vital
enzymes for cellular functions. 12 One of the topoisomerases, topoisomerase I, is only responsible for breaking
single-stranded DNA. 13 It was discovered that the growth of cancer cells might be prevented by blocking this
breaking activity. Investigations of new metal complexes as potential topoisomerase I inhibitors are important
since most of the known topoisomerase inhibitors exhibit several limitations such as poor solubility, dose-limiting
toxicity, reversibility of cleavage complex formation, and also developed resistance mechanisms. 14 Because of
the deleterious eﬀects of free radicals, it is worth investigating the complexes with strong antioxidant activity
in addition to their DNA-binding properties and cleavage activities. 15
To explore new chemical nucleases and anticancer drugs that are less toxic than those currently known
(cisplatin), Mn(II), Co(II), Ni(II), Cu(II), and Zn(II) metal complexes of 2-hydroxy-5-[(E)-(4-phenyl) diazenyl]
benzaldehyde oxime (H 2 L 1 , 1) and 2-hydroxy-5-[(E)-(4-nitrophenyl) diazenyl] benzaldehyde oxime (H 2 L 2 , 2)
ligands were investigated in terms of their DNA binding ability, DNA cleavage activity, and antioxidant eﬃciency
on DPPH (2,2’-diphenyl-1-picrylhydrazyl) free radicals, hydroxyl radicals, and superoxide anions. Because
colorectal cancer is among the most common cancers worldwide, 16 the cytotoxic eﬀect of the complexes on
human colon cancer cells (WiDr) was determined and their selectivities were evaluated on normal colon human
cells (CCD 841 CoN) and foreskin fibroblast cells. This was because it is preferential to find a molecule that
can kill cancer cells without significant toxicity to normal cells.

2. Results and discussion
2.1. Characterization
Analytical and physical data of the mononuclear Mn(II), Co(II), Ni(II), Cu(II), and Zn(II) complexes (1a–1e
and 2a–2e) are presented in Section 3. The structures of the ligands and their complexes (Figure 1) were
characterized by using elemental analysis, 1 H- and 13 C NMR, IR, UV-Vis, and mass spectral data. In the
structure proposed, the ligands have NO donors to form mononuclear metal complexes possessing metal/ligand
in 1:2 molar ratios. The stoichiometries of the complexes determined by mass and elemental analysis correspond
to the general formula [M(HL 1 or 2 )2 ] {where M is Mn(II), Co(II), Ni(II), Cu(II), or Zn(II) and HL 1 or 2 are
deprotonated oxime ligands}. Bivalent metal complexes are stable in air and the data of magnetic moment and
electronic spectra are suitable for valences of metal ions in the complexes. The ligands have good solubilities
in ethyl acetate, dimethylformamide (DMF), and dimethyl sulfoxide (DMSO) and low solubilities in ethyl
alcohol and chloroform. The solubilities of the complexes are variable and lower than those of the ligands. The
complexes are only soluble in DMF and DMSO.
The IR spectra provided enough information to elucidate how the ligands bond to the metal ions. The
IR spectra of ligands 1 and 2 show ν (C=N) and ν (=N-OH) peaks at 1633 and 3404 and at 1603 and 3361
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Figure 1. The structures of the proposed mononuclear complexes.

cm −1 , respectively. The IR spectra of all the complexes show ν (C=N) bands at 1592–1645 cm −1 and it is
found that the ν (C=N) bands in the complexes are shifted by about 1–41 cm −1 to the higher/lower energy
regions compared to the free ligands. 17 A broad phenolic OH peak of free ligands 1 and 2 at about 3100–3200
cm −1 disappears on complexation. This phenomenon appears to be due to the coordination of the azomethine
nitrogens and phenolic oxygens to the metal ion. 18
The assignment of bands to various M-N and M-O stretching vibrations in the lower region of the spectra
is diﬃcult as the ligand vibrations interfere. Hence, the assignments made here tentative. In light of previous
results 19 we assigned bands in the regions of 476–495 and 510–554 cm −1 for 1a–1e and 471–488 and 500–539
cm −1 for 2a–2e to ν (M-N) and ν (M-O) stretching vibrations, respectively. Results of FT-IR spectra analysis
strongly authenticate the formation of oxime type ligands (H 2 L 1 and H 2 L 2 ) and the complexes 1a–1e and
2a–2e.
The 1 H NMR spectra of the ligands (1 and 2) show two singlets at δ 8.393 and 8.384 ppm, respectively,
corresponding to the N=CH imine proton resonance. The singlets at δ 11.604 and 11.552 ppm correspond to
the C=N–OH proton resonance, respectively, and these singlets disappear on deuterium exchange. The NMR
spectra of 1d, 1e, and 2e could not be taken due to their low solubilities. The spectrum of diamagnetic
Ni(II) complex 2c was only recorded in d 6 -DMSO solution using tetramethylsilane (TMS) as the internal
standard. Singlets belonging to imine and oxime protons at δ 8.384 and 11.552 ppm, respectively, in the
spectrum of 2 shifted to 8.184 and 11.478 ppm. The phenolic OH proton signal at δ 11.135 also disappeared.
These observations are the consequence of ligand coordination to the nickel(II) ion via azomethine and phenolic
oxygen atoms.
Analysis by ESI mass spectral data of the complexes derived from ligands 1 and 2 indicated ions at m/z
599 (2.6%) [M+CH 3 CN+Na] + for 1a, at m/z 539 (42.6%) [M] + for 1c, at m/z 548 (5.3%) [M-OH+Na] + for
1d, at m/z 384 (46.2%) [M+3H-2C 6 H 5 N-2OH] + for 1e, at m/z 536 (13.3%) [M+CH 3 OH] + for 2a, at m/z
711 (20.7%) [M+2CH 3 CN] + for 2b, at m/z 333 (17.6%) [M-C 13 H 9 O 5 N 4 ] + for 2d, and at m/z 334 (16.8%)
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[M-C 13 H 9 O 5 N 4 ] + for 2e. The mass spectra of 1b and 2c could not be taken because the compounds could
not be ionized.
The electronic spectra of the ligands and their mononuclear complexes were obtained in DMF solutions
in the region of 200–900 nm at room temperature. The spectrum of H 2 L 1 shows absorption bands in two
regions at 396 nm ( ε = 30,080 M −1 cm −1 ) and 359 nm ( ε = 39,820 M −1 cm −1 ), 334 nm ( ε = 33,240 M −1
cm −1 ), 313 nm ( ε = 38,410 M −1 cm −1 ), and 296 nm (ε = 39,810 M −1 cm −1 ) . The spectrum of H 2 L 2 shows
absorption bands in three regions at 607 nm (ε = 3480 M −1 cm −1 ) , 387 nm ( ε = 18,900 M −1 cm −1 ) and
302 nm ( ε = 13,930 M −1 cm −1 ), and 269 nm (ε = 12,470 M −1 cm −1 ). The bands appearing at the low
energy side are attributable to n→ π * transitions associated with the azomethine chromophores. The bands at
the higher energy side are attributable to π → π * transitions between aromatic rings and the azo unit in the
ligands. The nitro-substitute ligand, H 2 L 2 , shows a significant red shift because of the increase of conjugation
length in the chromophore.
The ultraviolet spectra of the complexes are dominated by the absorptions of ligand(s). Absorption
bands belonging to ligands were broadened as located in the visible region with the complexation. Ligand field
absorptions of the Mn(II) complexes (1a, 2a) are not observed at energies below 20000 cm −1 . The spectra of
complexes 1a–1e and 2a–2e in DMF exhibit a band between 470 and 589 nm. 20−23 The observed magnetic
moment values and electronic spectra of the complexes suggest a tetrahedral geometry for the Mn(II) (1a,
2a), Co(II) (1b, 2b), and Zn(II) (1e, 2e) complexes and a square planar geometry for the Cu(II) and Ni(II)
complexes (1c, 2c and 1d, 2d). 24
2.2. DNA binding
2.2.1. Absorption spectra
To understand the eﬀect of a coordination compound on DNA as an anticancer drug is very important. Binding
of the molecules on DNA may occur in various ways depending on their charges. Although it is diﬃcult to
precisely determine the binding mode of the molecules to DNA, electronic absorption spectroscopy is the most
useful method for determining the binding mode. 25 This is because the changes observed in the spectrum can
provide information about the type of interaction, and the size of spectral change is proportional to the strength
of binding. 26 The absorption spectra for 1 and 2e as representative examples are shown in Figure 2. For the
others, similar spectra were obtained. As can be clearly understood from Figure 2, with the addition of DNA,
the absorption intensities belonging to both the ligand and the complex gradually decreased. At about 347
nm, hypochromicity was observed at about 15% with a very low bathochromic shift (0.5 nm) for 1. For 2e, at
402.50 nm, 46% hypochromicity with 5 nm of red shift was obtained. The values obtained for the others are
given in Table 1.
It can be understood from Table 1 that with the addition of calf thymus (CT) DNA to molecules, a
decrease in the maximum absorbance (hypochromism) and a shift at the wavelength belonging to the maximum
absorbance was observed for almost all the molecules studied (except 1b and 1d) at diﬀerent rates. The red
shift was observed in the case of the some molecules, but a hypsochromic shift occurred for others. Evaluating
these two diﬀerent situations, it can be said that all the molecules studied bound to CT-DNA via intercalation.
Intercalation ability of the complexes was attributed to partial insertion of planar aromatic ligands in between
the DNA base pairs. 27 Because the extent of spectral change is concerned with the strength of binding, it can
be said that the Mn complex of 2 (2a) bound the DNA most eﬀectively compared to the others.
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Figure 2. Absorption spectra of the 2-hydroxy-5-[(E)-(4-phenyl) diazenyl] benzaldehyde oxime ligand (1) and the Zn
complex of the 2-hydroxy-5-[(E)-(4-nitrophenyl) diazenyl] benzaldehyde oxime ligand (2e) (1.5 × 10 −5 M) in the absence
(—) and presence of increasing amounts of CT-DNA (0–38 µ M) at 25

◦

C in 5 mM Tris-HCl/50 mM NaCl buﬀer (pH

7.2). Arrow shows the absorbance changing upon increasing DNA concentrations (6 (—), 12 (—), 18 (—), 23 (—), 28
(—), 33 (—), 38 (—) µ M).
Table 1. UV-Vis absorption data of the ligands and complexes after the interaction with CT-DNA.

Compounds
1
2
1a
1b
1c
1d
1e
2a
2b
2c
2d
2e

λmax
free (nm)
347
370
366
379
309/363
360.50
278.50/350.50
373
467
429
440
402.50

λmax
bound (nm)
347.50
395
364.50
379
301/371
360.50
276/351
384
477.50
421
429
407.50

∆λ (nm)
0.5
25
1.5
0
8/8
0
2.5/0.5
11
10.5
8
11
5

Hypochromicity
∆Abs (%)
15
29
21
38
34/40
28
17/31
68
21
15
30
46

2.2.2. Competitive binding
A competitive ethidium bromide (EB) binding study was carried out in order to demonstrate whether drugs
could replace EB, a known DNA intercalator. 28 When EB intercalates with DNA, the maximum absorption of
free EB at 480 nm shifts to a higher wavelength and a decrease in absorption is observed. This observation is
proof for the intercalation of EB into the DNA. 29 It may be seen from Figure 3 that the absorption maxima
of free EB shifted to 482 nm in the presence of DNA. Addition of 1b (as a representative) to the EB-DNA
solution caused an increment in the absorption intensity, which is an indication of competitive binding of 1b
with EB to bind to DNA. Similar trends were observed for all other molecules. The results clearly suggest that
the investigated oxime ligands and their transition metal complexes bind to DNA in an intercalative mode.
2.2.3. Topoisomerase I inhibition
Topoisomerase I, an enzyme that unwinds DNA during transcription or replication, is an important cellular
target for anticancer treatment. 12,30 It is known that DNA intercalators can significantly interfere with these
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Figure 3. Absorption spectra of EB bound to DNA in the absence and presence of increasing amount of 1b. (—): 40
µ M EB, (. . . ): 40 µ M EB + 40 µ M CT-DNA, (—): 40 µ M EB + 40 µ M CT-DNA + 1b (5, 7.5 µ M). Arrow ( ↑)
shows the absorbance changes upon increasing complex concentration.

physiological processes by occupying the topoisomerase-binding site on DNA or forming stabilized ternary
complexes. 30 As shown in Figure 4, supercoiled plasmid DNA (pBR322) (line 1) was fully relaxed by human
topoisomerase I (line 2) in the absence of ligands or complexes. However, this relaxation was not observed when
the molecules at 0.4 mM were added to the mixture of enzyme and plasmid DNA. The DNA relaxation was
moderately prevented in the presence of all molecules studied. The eﬀects of all molecules were almost identical,
except for 2d and 2e. Because of the rate of transformation of relaxed DNA to supercoiled DNA, they had the
least eﬀect.

Figure 4. Inhibition eﬀect of the investigated ligands and complexes on topoisomerase I enzyme. I: DNA (250 ng), II:
DNA + human topoisomerase I (0.3 U). Other lines: DNA + human topoisomerase I + compounds (0.4 mM; identified
with the codes of the studied molecules according to Figure 1).

2.3. DNA cleavage activity
2.3.1. Hydrolytic cleavage activity
The agarose gel electrophoresis images for 1 and 2c (as representative examples) obtained using diﬀerent buﬀer
solutions to determine the eﬀects of pH are given in Figure 5. At pH 6 provided by Tris-HCl buﬀer, 1 and 2c
were the most eﬀective. Similar results were obtained for the others. The optimum pH for nuclease activity
of the molecules investigated was usually provided at values higher than 6 in the Tris-HCl buﬀer. When the
phosphate buﬀer was used, nuclease activity was much lower in the case of many of the molecules. This result
has been commented on by Zhu et al. 31 as showing that the binding site of the metal complex was the negatively
charged phosphates of the DNA backbone. The binding event between molecules and DNA might be inhibited
by the competition of the phosphates in the buﬀer with the phosphates on the DNA backbone.
To assess the dependency on concentration, pBR322 DNA was incubated for 6 h with diﬀerent concentrations of the molecules in the Tris-HCl buﬀer at the pH value determined as optimum. As observed in Figure
733
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Figure 5. pH dependence of the nuclease activity of 1 and 2c. 1: DNA control, 2–5: phosphate (NaH 2 PO 4 -Na 2 HPO 4 )
buﬀer was used; 6–10: Tris-HCl buﬀer was used. 2 and 7: pH 6; 3 and 8: pH 7; 4 and 9: pH 8; 5 and 10: pH 9; 6: pH 5.

6, with increasing 2d concentrations (10–500 µ M), the cleavage was found to be much more eﬃcient and there
was a gradual decrease in the amount of the supercoiled form with a simultaneous increase in the nicked form.
Similar results were obtained for 2a and 1c. In the case of free ligands, an increase in concentration did not contribute to the cleavage activity even at 2 mM (Figure 6, 2). With an increasing concentration of the molecules,
form II increased gradually, but form III (linear DNA) did not occur for most of the complexes. It can thus be
concluded that the complexes have weak nuclease activity. The linear form was only observed in the presence
of 0.5 mM of 1c. The most eﬀective cleavage profile was observed for 2a in that form III appeared before
the disappearance of form I (Figure 6, lane 2). This phenomenon indicates that the complex had an ability to
cause direct double-strand scission. 32 Due to the disruption of DNA into small pieces, EB staining could not
be observed in the presence of 2a at concentrations higher than 50 µ M. At 10 µ M the nuclease activity of 1a,
1b, 1d, 2b, and 2e was the most eﬀective. Interestingly, any further increase in the concentration of these
molecules resulted in suppression of DNA-cleaving ability. The results obtained from the cleavage reactions are
consistent with the results obtained from the DNA binding studies. In the DNA binding studies, a high degree
of hypochromicity was observed in the presence of 2a.

Figure 6. Concentration dependence of the nuclease activity of 2, 2d, and 2a. 1: DNA control. 2–5: 0.1–0.25–0.5–1–2
mM for 2; 10–50–100–250–500 µ M for 2d; 0.25–0.5–1–5–10–50–100 µ M for 2a.
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To test the ionic strength eﬀect, except for addition of NaCl at diﬀerent concentrations, the molecule
concentration and the medium pH were used according to values determined from previous experiments. At
low salt concentrations an increase was first observed for cleavage activity, and then a decline occurred as
concentration increased. This can be clearly seen in Figure 7 for 2c. At concentrations above 10 mM NaCl,
the nuclease activity decreased prominently in the case of most of the molecules. These results imply that the
electrostatic interaction can influence the DNA cleavage reaction to some degree. 31

Figure 7. Ionic strength and reaction time dependence of nuclease activity of 2c and 2a, respectively. 1: DNA control
for both 2a and 2c; 2–9: 0–2.5–5–10–50–100–250–350 mM NaCl added to the reaction mixture for 2c; 2–5: 12, 2 6, 3,
and 1 h for 2a.

With increased reaction time, the amount of form II increased and form I gradually disappeared. Form
III even appeared for some of the molecules after 3 or 6 h. That is to say, cleavage of DNA by the complexes
studied is dependent on the reaction time. Similar results are also available in the literature. 33,34 The reverse
is not available in the literature. However, the results of several investigations revealed that the extension of
the incubation time for cleavage reaction had no eﬀect. 35 In particular, 1a, 1c, 1e, 2a, and 2e exhibited higher
nuclease activity compared to the others. This is understood from the appearance of smears on the agarose gel
electrophoresis images. 36 An image indicating time-dependent activity for 2a is given in Figure 7. During the
studied incubation periods, control experiments using DNA alone were performed, but no significant cleavage
of pBR322 DNA was monitored (data not presented).

2.3.2. DNA cleavage mechanism
DNA cleavage experiments were carried out in the presence of some standard radical scavengers to investigate
which mechanism was responsible for DNA cleavage mediated by the ligands/complexes. 37 NaN 3 , L-histidine,
KI, ethanol (EtOH), methanol (MeOH), tert-butyl alcohol (t -BuOH), and DMSO did not alter the DNA
cleavage activity of the ligands/complexes as shown in Figure 8 for 2e (as representative). This rules out the
possibility of cleavage by singlet oxygen, hydroxyl radical, and hydrogen peroxide. However, in the presence
of catalase, while waiting for a similar result to be obtained for KI, an unexpected result was encountered. In
the presence of catalase, a smear formation was observed with increasing activity. Superoxide dismutase (SOD)
had a distinct influence on the DNA cleavage, suggesting that the superoxide anion is involved in the cleavage
735
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process. EDTA (Figure 8, lane 12) eﬃciently inhibited the DNA cleavage activity of the complexes, but in the
case of the ligands it was not found to have any eﬀect. EDTA, a metal-chelating agent that strongly binds to the
metal ion in the complex structure forming a stable complex, can eﬃciently inhibit DNA cleavage, indicating
that the complexes play the key role in cleavage. 33

Figure 8. The gel image of hydrolytic cleavage of pBR322 DNA by 2e in the presence of various radical scavengers:
1: DNA control (200 ng); 2: DNA + 2e (5 µ M) + 3: DNA + 2e + NaN 3 (0.1 M), 4: DNA + 2e + L-histidine (30
mM), 5: DNA + 2e + KI (0.1 M), 6: DNA + 2e + catalase (50 µ M), 7: DNA + 2e + EtOH (2 µ L), 8: DNA + 2e +
t -BuOH (2 µ L), 9: DNA + 2e + MeOH (2 µ L), 10: DNA + 2e + DMSO (2 µ L), 11: DNA + 2e + SOD (30 µ M),
12: DNA + 2e + EDTA (5 mM).

2.3.3. Oxidative DNA cleavage
The eﬀect of several external agents, such as H 2 O 2 , ascorbic acid (AA), mercaptoethanol (ME), and dithiothreitol (DTT), on nuclease activity was evaluated. Reaction mixtures were prepared to contain supercoiled
DNA, 25 µ M complex/125 µ M ligand, and one of these auxiliary reagents at diﬀerent concentrations: H 2 O 2
(0.4 M), AA (2.5 mM), ME (0.4 M), and DTT (0.32 mM) in buﬀer. The incubation period was 3 h at 37 ◦ C.
Furthermore, control experiments were carried out in the presence of these coreagents together with pBR322 in
the absence of the ligands/complexes under similar experimental conditions and no significant DNA cleavage
was observed (Figure 9, DNA).
The inductive eﬀects of the H 2 O 2 , DTT, and AA were almost equal for most of the ligands/complexes.
However, ME did not change or even reduce the activity in many cases. The agarose gel electrophoresis images
for 1a and 2a (as representative examples) are shown in Figure 9. Because the concentrations of the DTT and
AA in the reaction medium were less than that of H 2 O 2 , it can be concluded that the activator eﬀect of the
H 2 O 2 was weaker than the others. Increased activity in the presence of H 2 O 2 may be associated with increased
production of hydroxyl radicals. 38 In particular, the inductive eﬀect of the AA was greatest for 1a, 1d, 1e,
and 2e. As a result of these experiments, it can be said that complexes can cleave DNA both in hydrolytic and
oxidative ways. However, the hydrolytic cleavage of DNA is more advantageous than the oxidative cleavage. 39
2.4. Antioxidative activity
Molecules with antioxidant properties potentially have a crucial role for the elimination of the reactive oxygen
species (ROS) and repair of damaged DNA. Furthermore, it is a well-known fact that transition metal complexes
have significant antioxidative activity. 40,41
It is extremely important to reveal the hydroxyl radical scavenging activity of a compound. It can be
seen from Table 2 that the SC 50 values calculated for ligands and complexes are significantly lower than the
value found for mannitol. This means that the hydroxyl radical scavenging activity of the molecules investigated
is much greater than that of standard mannitol. A similar result in the literature was reported by researchers
working on Y(III) and Eu(III) complexes of naringenin-2-hydroxy benzoyl hydrazone ligand. 42 The hydroxyl
radical scavenging capacities of the molecules were almost the same, except 1, which had the lowest activity.
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Figure 9. Nuclease eﬃciency of the ligands/complexes in the presence of the auxiliary reagents. 1: DNA + complex;
2: DNA + complex + H 2 O 2 (0.4 M); 3: DNA + complex + ME (0.4 M); 4: DNA + complex + AA (2.5 mM); 5: DNA
+ complex + DTT (0.32 mM). In the control experiment, which was carried out only with DNA, there was no complex
in the reaction medium.

Several transition metal mixed-ligand complexes with flexible geometric transformations around the metal
centers, especially Mn, Cu, or Zn, can act as SOD enzymes even though their structures are totally unrelated
to the native enzyme. 5 The calculated SC 50 value for the native SOD enzyme was much lower than those
for the molecules studied, but the activities of the ligands and complexes were comparable to the results of
previously studied molecules in the literature, such as Co and Zn complexes of the 2, 6-di((phenazonyl-4-imino)
methyl)-4-methylphenol ligands. 43 The molecules investigated in the present study may be used as the SOD
enzyme mimic.
The DPPH free radical scavenging activity of all the complexes was higher than the activity of butylated
hydroxyanisole (BHA). The activity of AA was lower than that of most of the complexes, too. As a result, it can
be said that the complexes investigated are more eﬀective radical scavengers compared to standard antioxidants.
To summarize, complexes generally have higher antioxidant capacities than ligands. The activity could be
enhanced by the presence of metal ions. The antioxidant activity of the molecules is related to their molecular
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Table 2. Antioxidative activities expressed as SC 50 of the ligands and complexes by comparison with standards.

Compounds
and standards
1
2
1a
1b
1c
1d
1e
2a
2b
2c
2d
2e
SOD
Ascorbic acid
BHA
Mannitol

SC50 (SOD)
(µM)
52.5
175.4
57.9
51.0
108.6
76.6
128.6
38.8
86.5
278.2
87.3
37.4
0.025
-

SC50 (DPPH)
(µM)
330.76
74.15
60.70
19.54
45.74
10.80
63.14
28.63
2.71
4.03
11.90
6.30
27.05
147
-

SC50 (HRSA)
(µM)
107.86
6.18
4.38
6.07
18.66
5.58
4.14
25.03
1.97
2.42
4.86
5.07
10,860

structures, but complexation with the metal ions may aﬀect the chemical properties of ligand molecules, hence
the variation in the activity. 44
2.5. Cytotoxic findings
Cytotoxic studies are generally performed by MTT assay. MTT (3-,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide), a water-soluble tetrazolium salt, is converted to an insoluble purple formazan within the mitochondria. This formazan product is impermeable to cell membranes and thus accumulates in healthy cells. 45
However, newer tetrazolium salts such as MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4sulfophenyl)-2H-tetrazolium), WSTs (water-soluble tetrazolium salts), and XTT (2,3-bis-(2-methoxy-4-nitro-5sulfophenyl)-2H-tetrazolium-5-carboxanilide) can pass back out of the cell after reduction. For this reason, the
WST-1 method was preferred in this study. 46
The studied ligands/complexes were evaluated in terms of their antiproliferative eﬀects and selectivity on
human colon adenocarcinoma, human colon, and human foreskin fibroblast cell lines. In this way, all the results
obtained could be more valuable. Results were calculated as IC 50 (µ g/mL) and compared with the results
obtained for cisplatin (Table 3). Except for the Zn(II) complex of the 2-hydroxy-5-[(E)-(4-phenyl) diazenyl]
benzaldehyde oxime ligand (1e), the others were not as eﬀective as cisplatin on human colon adenocarcinoma.
However, other molecules, especially 2e and both of the ligands, also had substantial activity. It is notable that
1e was more active than cisplatin.
The main objective of the studies in the field of new anticancer drug development is for them to have
higher eﬃciency and selectivity than the existing anticancer drugs. 47 Eﬃciency for a newly synthesized drug
should be eﬀective at lower concentrations than the reference drug on cancer cell lines. From this point of
view, it can be seen that 1e was more eﬀective than the cisplatin and other complexes on the used cell lines.
However, selectivity for a new drug is known to mean that the drug must be ineﬀective on healthy cell lines at
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Table 3. Eﬀect of molecules on the viability of cells (IC 50 , µ g/mL).

Compounds
1
2
1a
1b
1c
1d
1e
2a
2b
2c
2d
2e
Cisplatin

Cell line
WiDr
2.31 ± 0.09
3.06 ± 0.33
4.83 ± 0.05
> 10
8.61 ± 0.65
> 10
0.77 ± 0.01
8.79 ± 0.50
8.87 ± 1.50
7.96 ± 0.25
9.33 ± 0.40
1.90 ± 0.05
0.99 ± 0.06

Colon normal
3.95 ± 0.12
3.64 ± 0.13
3.22 ± 0.02
> 10
> 10
> 10
1.89 ± 0.13
> 10
8.87 ± 0.19
9.42 ± 0.48
> 10
2.83 ± 0.16
2.99 ± 0.07

Fibroblast
3.46 ± 0.06
7.71 ± 0.30
3.24 ± 0.15
> 10
6.03 ± 0.30
> 10
1.49 ± 0.07
6.04 ± 0.70
> 10
> 10
> 10
1.65 ± 0.10
5.18 ± 0.12

the concentration at which it reduces the proliferation of cancer cells. When considered from this perspective,
1e once more came into prominence among the other molecules, but its selectivity was lower than cisplatin. The
findings of the cytotoxic activities confirmed the binding of the complexes to DNA at varying degrees, which
consequently leads to cell death. Except for 1e, both of the ligands (1 and 2) and 2e also inhibited cell growth
at a rate of 50% at extremely low concentrations. It is thought that this situation was due to the synergistic
eﬀect between ligands and the central metal atom, because 1e and 2e are the Zn complexes of the studied
oxime ligands. Furthermore, it was found in the DNA binding studies that the complexes mentioned showed
moderate hypochromicity compared to other complexes. In addition to this, they had nuclease activity, which
could convert the supercoiled plasmid DNA to the linear form at a low concentration of 10 µ M. On the other
hand, the topoisomerase inhibition eﬃciency of 2e was found to be very high.
In conclusion, ten transition metal complexes were prepared and characterized with the two azo-oxime
ligands. All the complexes interacted with DNA via intercalation at diﬀerent degrees. The complexes had
the ability to cleave supercoiled DNA by hydrolytic and oxidative means. Because of their potentials as
topoisomerase inhibitors and antioxidants they may be evaluated as anticancer drugs that are alternatives
to cisplatin. In particular, one of the complexes, 1e, had a cytotoxic eﬀect on human colon cancer cells. All of
them also had greater free radical scavenging activities than standard antioxidants.
The next step for this study should be the investigation of signaling pathways for apoptosis and cell
proliferation of 1e and 2e on the same cell lines for elucidating the possible mechanism of the determined
eﬃciency and selectivity of these complexes. To improve the selectivity of 1e, new designs based on coordination
chemistry should be formulated.

3. Experimental
3.1. Chemicals
All chemicals used throughout the study were of analytical reagent grade and were provided commercially by
Sigma. Double-distilled water was used for all experimental processes. Fetal bovine serum (FBS) was obtained
from Biochrom (Berlin, Germany), penicillin-streptomycin from GIBCO (Paisley, UK), and trypsin-EDTA solu739
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tion from Biological Industries (Kibbutz Beit Haemek, Israel). WST-1 ((2-(4-iodophenyl)-5-(2,4-disulfophenyl)2H-tetrazolium, monosodium salt) cell proliferation reagent was purchased from Roche Diagnostics GmbH
(Mannheim, Germany). Eagle’s minimum essential medium (EMEM) and the cell lines were purchased from
the American Type Culture Collection (Manassas, VA, USA).
2-Hydroxy-5-[(E)-(4-phenyl)diazenyl]benzaldehyde oxime (1) and 2-hydroxy-5-[(E)-(4-nitrophenyl)diazenyl]benzaldehyde oxime (2) were prepared by the modification of the reported method, 48,49 and their complexes investigated in terms of interactions with DNA were prepared by the reported methods. 50
3.2. Instrumentation
Melting points (mp) were determined on a Barnstead/Electrothermal 9100 apparatus in open capillary tubes.
The FT-IR spectra were measured as KBr pellets on a PerkinElmer 100 FT-IR spectrometer. 1 H NMR
spectra were recorded on a Varian Gemini 200 and Varian Mercury 400 spectrometer using DMSO-d 6 as the
solvent. Chemical shifts (δ) were reported in parts per million (ppm) relative to an internal standard of Me 4 Si.
Elemental analyses were determined on a Costech 4010 CHNS instrument. The metal content of the complexes
was determined by a Spectro Genesis Optical emission spectrometer with inductively-coupled plasma (ICP)
excitation and electrospray ionization mass spectrometry (ESI-MS) was performed on a Thermo Quantum
Access Max LC-MS/MS spectrometer. Electrical conductivities of complex solutions in dimethylformamide
(approximately 10 −3 M, DMF) were measured at room temperature with a Hanna EC 215 conductivity meter
by using 0.01 M KCl water solution as the calibrant.
Electronic absorption spectra of all studied molecules were recorded in the absence and presence of CTDNA on a Shimadzu UV-1800 UV-Vis spectrophotometer from 200 to 600 nm. Cleavage experiments were
performed with the help of the Wide Mini-Sub Cell GT System (Bio-Rad) supported by PowerPacBasic (BioRad), and gel patterns of electrophoresis were visualized under UV light and photographed by the QUANTUM
ST5 (Vilber Lourmat) gel documentation system.
3.3. Synthesis of the ligands
3.3.1. 2-Hydroxy-5-[(E)-(4-phenyl)diazenyl]benzaldehyde oxime, H 2 L 1 (1)
A solution of 2-hydroxy-5-[(E)-phenyldiazenyl]benzaldehyde (1.0 g; 4.4 mmol) and HONH 2 ·HCl (0.93 g; 13
mmol) in dry pyridine (90 mL) were stirred at room temperature for 48 h and then the mixture was poured
into ice-cold H 2 O (300 mL). The resulting yellow precipitate was collected, washed successively with ice cold
H 2 O and petroleum ether several times, recrystallized from hot ethyl acetate-petroleum ether, and dried in a
desiccator over CaCl 2 .
Yellow; yield 94%; mp: 155 ◦ C. Anal. calc. for C 13 H 11 N 3 O 2 : C, 64.72; H, 4.60; N, 17.42. Found: C,
64.66; H, 4.67; N, 17.51%. UV/Vis (DMF) λmax (ε): 296 (39,810); 313 (38,410); 334 (33,240); 359 (39,820);
396 (30,080). IR (cm −1 ) : 3404 ν (N-OH); 1633 ν (C=N); 1481 ν (N=N); 1224 ν (C-O).

1

H NMR (400 MHz,

DMSO-d 6 ) δ : 7.065, 7.043 d. (Ar-1H, J = 8.8 Hz); 7.5–7.04 m. (Ar-3H); 7.8–7.78 m. (Ar-3H); 8.082 s. (Ar-1H);
8.393 s. (1H, H-C=N); 11.604 s. (1H, C=N-OH); 10.958 s (Ar-OH). MS(ESI-m/z): 242 [M] + .
3.3.2. 2-Hydroxy-5-[(E)-(4-nitrophenyl)diazenyl]benzaldehyde oxime, H 2 L 2 (2)
H 2 L 2 (2) was synthesized following the same procedure adopted for H 2 L 1 (1) using 2-hydroxy-5-[(4-nitrophenyl)
diazenyl] benzaldehyde (1.222 g, 4.4 mmol) instead of 2-hydroxy-5-[(E)-phenyldiazenyl] benzaldehyde.
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Brown; yield 67%; mp: 202 ◦ C. Anal. calc. for C 13 H 10 N 4 O 4 : C, 54.55; H, 3.52; N, 19.57. Found: C,
54.62; H, 3.53; N, 19.53%. UV/Vis (DMF) λmax (ε) : 269 (12,470); 302 (13,930); 387 (18,900); 607 (3480). IR
(cm −1 ): 3361 ν (N-OH); 3130 ν (OH); 1603 ν (C=N); 1488 ν (N=N); 1336 ν (NO 2 ); 1271 ν (C-O).

1

H NMR

(200 MHz, DMSO-d 6 ) δ : 7.062, 7.107 d. (Ar-1H, J = 9.0 Hz); 7.855, 7.898 d. (Ar-1H, J = 8.6 Hz); 7.961,
8.006 d. (Ar-2H, J = 9.0 Hz); 8.172 s. (Ar-1H); 8.166, 8.209 d. (Ar-2H J = 8.6 Hz); 8.384 s. (Ar-1H, H-C=N);
11.135 s. (Ar-OH); 11.552 s. (C=N-OH). MS(ESI-m/z) : 287 [M+H] + .
3.4. Preparation of metal complexes (1a–1e, 2a–2e)
Complexes 1a–1e/2a–2e were synthesized following the same procedure adopted for complex 1a using
Co(ClO 4 )2 .6H 2 O (73 mg; 0.21 mmol), Ni(ClO 4 )2 .6H 2 O (76 mg; 0.21 mmol), Cu(ClO 4 )2 .6H 2 O (78 mg; 0.21
mmol), Zn(ClO 4 )2 .6H 2 O (78 mg; 0.21 mmol), and the related ligand (0.41 mmol), respectively, instead of
H 2 L 1 and Mn(ClO 4 )2 .6H 2 O.
1a: A solution of Mn(CO 4 )2 .6H 2 O (76 mg; 0.21 mmol) in 5 mL of ethanol was added dropwise to the
solution of H 2 L 1 (100 mg; 0.41 mmol) in 20 mL of ethanol and the resulting solution was stirred for 2 days at
room temperature. The pH of the solution was adjusted to 6.5 with ammonia. A precipitate was formed and
the mixture was additionally stirred for 1 h. The microcrystalline green solid product was isolated by filtration,
washed with H 2 O, and finally dried in a desiccator over CaCl 2 .
Green; yield 77%; mp: 261 ◦ C. Anal. calc. for C 26 H 20 N 6 O 4 Mn; C, 58.3; H, 3.8; N, 15.7; Mn, 10.3
Found: C, 58.2; H, 3.6; N, 16.0; Mn, 9.7. UV-Vis (DMF) λmax (ε): 273 (9040); 283 (9180); 338 (11,910); 382
(12,490); 390 (12,710); 505 (38,570). IR (cm −1 ): 3171 ν (N-OH); 1592 ν (C=N); 1464 ν (N=N); 1227 ν (C-O);
517 ν (M-O); 476 ν (M-N). Molar conductivity ( Ω−1 cm 2 mol −1 ) 5.3. µ eﬀ B.M. (298 K): 5.89 (per metal ion);
MS(ESI-m/z): 599 [M+CH 3 CN+Na] + .
1b: Brown; yield 97%; mp: 296 ◦ C. Anal. calc. for C 26 H 20 N 6 O 4 Co; C, 57.9; H, 3.7; N, 15.6; Co, 10.9
Found: C, 58.3; H, 3.8; N, 15.7; Co, 10.5. UV-Vis (DMF) λmax (ε) : 270 (37,900); 350 (40,100); 436 (51,700); 589
(29,990). IR (cm −1 ) : 3149 ν (N-OH); 1594 ν (C=N); 1465 ν (N=N); 1228 ν (C-O); 554 ν (M-O); 488 ν (M-N).
Molar conductivity ( Ω−1 cm 2 mol −1 ) 6.1. µ eﬀ B.M. (298 K): 4.14 (per metal ion); MS(ESI-m/z): it was not
taken because it could not be ionized.
1c: Khaki; yield 71%; mp: 270 ◦ C. Anal. calc. for C 26 H 20 N 6 O 4 Ni; C, 57.9; H, 3.7; N, 15.6; Ni, 10.9
Found: C, 57.7; H, 3.6; N, 15.5; Ni, 10.4. UV-Vis (DMF) λmax (ε): 359 (77,800); 365 (77,650); 392 (67,950); 498
(37,290). IR (cm −1 ) : 3395 ν (N-OH); 1643 ν (C=N); 1474 ν (N=N); 1227 ν (C-O); 510 ν (M-O); 495 ν (M-N).
Molar conductivity ( Ω−1 cm 2 mol −1 ) 3.8. µ eﬀ B.M. (298 K): diamagnetic; MS(ESI- m/z): 539 [M] + .
1d: Wheat; yield 83%; mp: 246 ◦ C. Anal. calc. for C 26 H 20 N 6 O 4 Cu; C, 57.4; H, 3.7; N, 15.4; Cu, 11.7
Found: C, 57.5; H, 3.4; N, 15.8; Cu, 11.8. UV-Vis (DMF) λmax (ε): 272 (9170); 357 (10,560); 389 (12,690); 449
(10,080). IR (cm −1 ) : 3180 ν (N-OH); 1645 ν (C=N); 1475 ν (N=N); 1229 ν (C-O); 535 ν (M-O); 490 ν (M-N).
Molar conductivity ( Ω−1 cm 2 mol −1 ) 2.6. µ eﬀ B.M. (298 K): 2.05; MS(ESI- m/z): 548 [M-OH+Na] + .
1e: Orange; yield 57%; dec: 263 ◦ C. Anal. calc. for C 26 H 20 N 6 O 4 Zn; C, 57.2; H, 3.7; N, 15.4; Zn, 12.0
Found: C, 56.9; H, 3.6; N, 15.1; Zn, 12.1. UV-Vis (DMF) λmax (ε) : 269 (64,350); 281 (63,700); 411 (10,640); 418
(10,420); 469 (33,180). IR (cm −1 ): 3180 ν (N-OH); 1637 ν (C=N); 1476 ν (N=N); 1231 ν (C-O); 519 ν (M-O);
476 ν (M-N). Molar conductivity (Ω−1 cm 2 mol −1 ) 9.4. µ eﬀ B.M. (298 K): diamagnetic; MS(ESI-m/z) : 384
[M+3H-2C 6 H 5 N-2OH] + .
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2a: Brown; yield 92%; mp: 229 ◦ C. Anal. calc. for C 26 H 18 N 8 O 8 Mn; C, 49.9; H, 2.9; N, 17.9; Mn, 8.8
Found: C, 50.3; H, 3.0; N, 18.0; Mn, 8.4. UV-Vis (DMF) λmax (ε): 271 (17,050); 395 (17,010); 470 (19,720). IR
(cm −1 ): 3360 ν (N-OH); 1600 ν (C=N); 1488 ν (N=N); 1338 ν (NO 2 ) ; 1271 ν (C-O); 512 ν (M-O); 473 ν (M-N).
Molar conductivity ( Ω−1 cm 2 mol −1 ) 3.2. µ eﬀ B.M. (298 K): 5.99; MS(ESI- m/z): 536 [M+H-2NO 2 ] + .
2b: Brownish violet; yield 94%; mp: 229 ◦ C. Anal. calc. for C 26 H 18 N 8 O 8 Co; C, 49.6; H, 2.9; N,
17.8; Co, 9.4 Found: C, 49.1; H, 2.9; N, 17.5; Co, 9.0. UV-Vis (DMF) λmax (ε): 274 (15,720); 385 (15,860);
497 (15,290). IR (cm −1 ): 3483 ν (N-OH); 1603 ν (C=N); 1476 ν (N=N); 1338 ν (NO 2 ); 1231 ν (C-O); 539
ν (M-O); 484 ν (M-N). Molar conductivity ( Ω−1 cm 2 mol −1 ) 11.0. µ eﬀ B.M. (298 K): 3.47; MS(ESI- m/z):
711 [M+2CH 3 CN] + .
2c: Deep green; yield 82%; mp: 240 ◦ C. Anal. calc. for C 26 H 18 N 8 O 8 Ni; C, 49.6; H, 2.9; N, 17.8; Ni, 9.3
Found: C, 49.7; H, 2.7; N, 17.6; Ni, 9.5. UV-Vis (DMF) λmax (ε): 268 (12,470); 312 (10,970); 388 (7670); 501
(4330). IR (cm −1 ): 3358 ν (N-OH); 1604 ν (C=N); 1488 ν (N=N); 1337 ν (NO 2 ) ; 1271 ν (C-O); 527 ν (M-O);
474 ν (M-N). 1 H NMR (200 MHz, DMSO-d 6 ) δ : 7.070, 7.113 d. (Ar-2H, J = 8.6 Hz ); 7.883, 7.920 d. (Ar-4H,
J = 7.4 Hz); 7.988, 8.029 d. (Ar-2H, J = 8.2); 8.183 s. (2H, HC=N); 8.373, 8.412 d. (Ar-4H, J = 7.8); 11.478 s.
(2H, C=N-OH). Molar conductivity (Ω−1 cm 2 mol −1 ) 8.8. µ eﬀ B.M. (298 K): diamagnetic; MS(ESI- m/z):
it was not taken because it could not be ionized.
2d: Brown; yield 82%; mp: 273 ◦ C. Anal. calc. for C 26 H 18 N 8 O 8 Cu; C, 49.2; H, 2.9; N, 17.7; Cu,
10.0 Found: C, 49.5; H, 2.9; N, 17.4; Cu, 9.7. UV-Vis (DMF) λmax (ε) : 272 (9820); 328 (6800); 375 (6240);
516 (13,070). IR (cm −1 ): 3234 ν (N-OH); 1606 ν (C=N); 1473 ν (N=N); 1336 ν (NO 2 ); 1230 ν (C-O); 500
ν (M-O); 471 ν (M-N). Molar conductivity (Ω−1 cm 2 mol −1 ) 4.2. µ eﬀ B.M. (298 K): 1.81; MS(ESI- m/z): 333
[M-C 13 H 9 N 4 O 5 ] + .
2e: Red brick; yield 81%; mp >300 ◦ C. Anal. calc. for C 26 H 18 N 8 O 8 Zn; C, 49.1; H, 2.8; N, 17.6;
Zn, 10.3 Found: C, 48.7; H, 2.5; N, 17.5; Zn, 10.3. UV-Vis (DMF) λmax (ε): 268 (12,690); 312 (10,970); 392
(16,561); 472 (16,010). IR (cm −1 ): 3420 ν (N-OH); 1604 ν (C=N); 1473 ν (N=N); 1340 ν (NO 2 ); 1260 ν (CO); 519 ν (M-O); 488 ν (M-N). Molar conductivity (Ω−1 cm 2 mol −1 ) 5.9. µ eﬀ B.M. (298 K): diamagnetic;
MS(ESI-m/z): 334 [M- C 13 H 9 N 4 O 5 ] + .

3.5. DNA binding studies
3.5.1. Preparation of stock solutions
A stock CT-DNA solution was prepared by dissolving the desired amount of DNA in the 5 mM Tris-HCl/50
mM NaCl buﬀer solution (pH 7.2) followed by stirring for 3 days at 4 ◦ C and the ratio of UV absorbance at 260
and 280 nm of the freshly prepared CT-DNA solution was calculated as ∼ 1.8–1.9:1, indicating that the DNA
was suﬃciently free of protein. The concentration of the solution was also determined by UV absorbance at
260 nm using the molar extinction coeﬃcient of 6600 M −1 cm −1 for DNA at this wavelength. The DNA stock
solution was stored at 4 ◦ C in the dark and needed to be consumed within a week after preparation. 51 The
concentrated stock solutions of the molecules for binding and cleavage studies were prepared by dissolving in
DMSO and DMF, respectively, and diluted appropriately to the required concentration with the corresponding
buﬀer for all the experiments, taking care that the final DMSO or DMF concentration never exceeded 10% v/v.
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3.5.2. Monitoring the absorption spectra
The absorption titration experiment was performed by maintaining the concentration of the free ligand or its
metal complex constant (15 µ M) and gradually increasing the concentration of CT-DNA (0–38 µ M). The
reference solution included Tris-HCl buﬀer solution and DMSO, the quantity of which was the same as the
amount in the sample cuvette. While measuring the absorption spectra, an equal amount of DNA was added
to both the compound solution and the reference solution to eliminate the absorbance of DNA itself. After
each addition of CT-DNA to the cuvettes, the resulting solution was allowed to equilibrate at 25 ◦ C for 10 min
before measurements were taken. The addition of CT-DNA during the process was repeated until there was
almost no change in the spectra, indicating that binding saturation had been reached. 52
3.5.3. Competitive binding
The competitive binding experiments were performed on a UV-Vis absorption spectrophotometer, unlike several
studies in the literature carried out with fluorescence spectrophotometers. 9 Absorption titrations were performed
by keeping the concentrations of the ethidium bromide (EB, 40 µ M) and DNA (40 µ M) constant, and by varying
the complex concentration (0–30 µ M) in 5 mM Tris-HCl/50 mM NaCl (pH 7.2) buﬀer solution. The variations
of the maximum absorbance of the EB in the presence of DNA or DNA+ligands/complexes were followed. 53
3.5.4. Topoisomerase I inhibition assay
Topoisomerase inhibition was determined by observing the relaxation of supercoiled DNA in the following way:
a reaction mixture containing 35 mM Tris-HCl (pH 8.0), 72 mM KCl, 5 mM MgCl 2 , 5 mM DTT, 2 mM
spermidine, 0.01% bovine serum albumin (BSA), 250 ng pBR322, 0.3 U of human topoisomerase, and potential
topoisomerase inhibitor (one of the ligands or complexes) was prepared and incubated at 37 ◦ C for 30 min. The
reaction in each tube was quenched by addition of gel loading buﬀer containing 0.2% bromophenol blue, 0.2%
xylene cyanol, 10% sodium dodecyl sulfate (SDS), and 30% glycerol. 54 Tube contents were loaded onto 0.8%
agarose gel containing 0.25 µ g/mL of EB. The electrophoresis was carried out for 4 h at 40 V in Tris-acetic
acid-EDTA (TAE) buﬀer. The bands were visualized under UV light and photographed.
3.6. Cleavage experiments
3.6.1. Hydrolytic DNA cleavage
To exhibit the dependence of the cleavage activity on various conditions, several experiments were performed
under diﬀerent conditions without an additional agent. 31
To determine the most eﬀective pH for cleavage reactions, reactions between plasmid DNA (250 ng) and
molecules were performed in 50 mM phosphate (for pH 6.0–9.0) and 50 mM Tris-HCl (for pH 5.0–9.0) buﬀer
solutions for 6 h at 37 ◦ C. Reactions were terminated by adding the loading buﬀer.
To demonstrate the dependence on ligand/complex concentration of the cleavage activity, reaction mixtures were constructed to contain diﬀerent concentrations of molecules.
By increasing the ionic strength in reaction medium by adding NaCl at diﬀerent concentrations (0–250
mM), the electrostatic contribution to the DNA cleavage was detected.
To determine ideal incubation time, reaction mixtures were prepared considering the values determined
earlier for pH and concentration of ligand/complex and NaCl, and they were incubated for diﬀerent periods of
time such as 1, 3, 6, and 12 h.
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3.6.2. Determination of the reactive oxygen species eﬀective at hydrolytic cleavage
Cleavage reactions were carried out in the presence of DMSO, t-BuOH, EtOH, and MeOH as hydroxyl radical
scavengers; NaN 3 and L-histidine as singlet oxygen scavengers; SOD as superoxide radical scavenger; EDTA as
chelating agent; and catalase and KI as H 2 O 2 scavengers. 33
3.6.3. Oxidative DNA cleavage
Oxidative cleavage activities were investigated by carrying out the reactions at 37 ◦ C for 3 h. Auxiliary reagents
(H 2 O 2 , AA, ME, and DTT) were added to reaction mixtures containing 200 ng of pBR322 in 50 mM Tris-HCl
(pH 7) buﬀer solution. 54
3.7. Antioxidative activity
3.7.1. DPPH radical-scavenging activities
To measure the DPPH free radical scavenging activities of the investigated molecules, absorbance of 1 mL
of 0.4 mM DPPH solution in methanol was measured at 517 nm (A blank ). Various concentrations of the
ligand/complex solutions were added to each DPPH solution. After a 30-min incubation period in the dark at
room temperature, the absorbance was read against a blank (A sample ). Activities (%) were calculated for the
various concentrations of molecules by the following equation:
Scavenging activity (%) = (A blank – A sample )× 100 / A blank
The SC 50 values, i.e. the concentration scavenging 50% of the free radicals in the medium, were calculated
by plotting values found for scavenging activities as a function of molecule concentrations. Performing the same
procedure for the BHA and AA as for the known antioxidants, the SC 50 values were also calculated and
compared with those obtained for the compounds.
3.7.2. Hydroxyl radical scavenging activities
Hydroxyl radical scavenging activities of the ligands/complexes were screened according to the deoxyribose
method modified by Hagerman et al. 55 Reactions were performed in 10 mM phosphate buﬀer (pH 7.4) containing
deoxyribose (2.8 mM), H 2 O 2 (2.8 mM), FeCl 3 (25 µ M), EDTA (100 µ M), and the ligand or complex as a
sample to be tested. Reactions were initiated with the addition of AA to the final concentration of 100 µ M and
the mixtures were incubated at 37 ◦ C for 1 h. Following the incubation, after the addition of thiobarbituric acid
(TBA, 1%) and then trichloroacetic acid (TCA, 2.8%) cooled with ice to the reaction mixtures, the resultant
mixtures were incubated in a boiling water bath for 20 min and gave yields with color formation. Mixtures were
transferred to n -butanol after cooling and the absorbance of each tube was measured against n -butanol at 532
nm. A ligand/complex-free reaction mixture was used as a blank. Under the same assay conditions, mannitol,
which is one of the natural antioxidants, was tested to compare it with the ligands’/complexes’ activity. SC 50
values were also calculated for all samples according to the procedure followed in the DPPH test.
3.7.3. Superoxide dismutase activities
For the determination of superoxide radical scavenging activity, the nitro blue tetrazolium (NBT) photoreduction
method was used and the SOD activity of the ligands/complexes was investigated by comparing the commercial
SOD enzyme from bovine erythrocytes. Superoxide radicals were generated in 50 mM phosphate buﬀer (pH 7.8)
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containing 0.1 M EDTA, 2 µ M riboflavin, 13 mM L-methionine, and 75 µM NBT. Solutions of molecules or
native enzyme at diﬀerent concentrations were added to each radical-producing mixture. Each reaction mixture
was incubated in the presence of a fluorescent light for 5 min and absorbances were measured at 560 nm. 56
By using the absorbance of the mixture in the absence of the tested compounds as the blank, the
percentage inhibition (I%) of NBT reduction was calculated as above. SC 50 values were also calculated following
the method used in the DPPH test. By comparing the values, molecules were evaluated for whether the
ligands/complexes were SOD equivalents or not.
3.8. Cell culture
The human colon adenocarcinoma cancer cell line (WiDr, ATCC-CCL-218), human colon normal cell line
(CCD 841 CoN, ATCC-CRL-1790), and human normal foreskin fibroblast cell line (ATCC-CRL-2522) were
purchased from the American Type Culture Collection (Manassas, VA, USA). All cells were cultured in EMEM
supplemented with 2 mM L-glutamine, 10% heat inactivated FBS, and 1% antibiotic solution (penicillin and
streptomycin) with a 5% CO 2 supply at 37 ◦ C.
3.8.1. Cytotoxicity assay
The cytotoxic potential of studied molecules was determined by WST-1 colorimetric assay based on succinate
dehydrogenase activity after treatment for 72 h. 57
Cisplatin was used as a reference chemotherapeutic. Cisplatin and all test compounds were dissolved in
DMSO. The final concentration of DMSO did not exceed 0.5% in culture media during any experiments, and
this concentration of DMSO did not aﬀect cell morphology or viability.
When enough cells were produced, cells were trypsinized and centrifuged at 130 ×g for 6 min and the
pellet was dissolved in the medium. The cell suspension was mixed with trypan blue and spread on a Neubauer
chamber to be counted by using an inverted microscope (Nikon Eclipse TS100, Japan). Cells were then added
to a 96-well flat-bottomed cell culture plate at a density of 5000 cells per well. The final volume of the wells
was completed to 200 µ L with medium. After removing the well contents at the end of 24 h, 200 µ L of fresh
medium was added to each well. At the same time the molecules studied and cisplatin at diﬀerent concentrations
(0–10 µ g/mL) were added to the medium. In this manner, cells were exposed to diﬀerent concentrations of
ligands and complexes. After removing the well contents at the end of 72 h, 90 µ L of fresh medium and 10
µ L of WST-1 reagent were added to each well and incubated at 37 ◦ C for 2 h. After the reaction period, the
samples were shaken for 1 min and absorbance was measured at 440 nm with 620 nm of reference wavelength
by a spectrophotometer (VersaMax; Molecular Devices, Sunnyvale, CA, USA). 57
All experiments were repeated on three independent days so that there were 6 wells for each drug
concentration. Optical densities (ODs) were used to determine % cell viabilities using the formula [(OD of
treated group / OD of control group) × 100] in treatment cells compared to control cells with no compound
exposure. 58 A log-concentrations versus % cell viabilities graph was plotted, and IC 50 values were determined
using this logarithmic graph. IC 50 represents the concentration in µ g/mL required for 50% inhibition of cell
growth compared to negative control cells. 59
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7. Altunoz Erdogan, D.; Ozalp-Yaman, Ş. J. Mol. Struct. 2014, 1064, 50-57.
8. Chen, G. J.; Qiao, X.; Qiao, P. Q.; Xu, G. J.; Xu, J. Y.; Tian, J. L.; Gu, W.; Liu, X.; Yan, S. P. J. Inorg. Biochem.
2011, 105, 119-126.
9. Tan, J.; Wang, B.; Zhu, L. Bioorg. Med. Chem. 2009, 17, 614-620.
10. 0 Lerman, L. S. J. Mol. Biol. 1961, 3, 18-30.
11. Rajalakshmi, S.; Weyhermüller, T.; Freddy, A. J.; Vasanthi, H. R.; Nair, B. U. Eur. J. Med. Chem. 2011, 46,
608-617.
12. He, X.; Jin, L.; Tan, L. Spectrochim. Acta A: Mol. Biomol. Spectrosc. 2015, 135, 101-109.
13. Palchaudhuri, R.; Hergenrother, P. J. Curr. Opin. Biotechnol. 2007, 18, 497-503.
14. Tabassum, S.; Afzal, M.; Arjmand, F. J. Photochem. Photobiol. B 2012, 115, 63-72.
15. Sathiyaraj, S.; Sampath, K.; Raja, G.; Butcher, R. J.; Gupta, S. K.; Jayabalakrishnan, C. Inorg. Chim. Acta 2013,
406, 44-52.
16. Volarevic, V.; Vujic, J. M.; Milovanovic, M.; Kanjevac, T.; Volarevic, A.; Trifunovic, S. R.; Arsenijevic, N. J.
BUON. 2013, 18, 131-137.
17. Suh, J.; Chei, W. S. Curr. Opin. Chem. Biol. 2008, 12, 207-213.
18. El-Sayed, B. A.; Abo Aly, M. M.; Emara, A. A. A.; Khalil, S. M. E. Vib. Spectrosc. 2002, 30, 93-100.
19. Karaoglu, K.; Baran, T.; Serbest, K.; Er, M.; Degirmencioglu, I. J. Mol. Struct. 2009, 922, 39-45.
20. Armitage, B. Chem. Rev. 1998, 98, 1171-1200.
21. Lever, A. P. B. Inorganic Electronic Spectroscopy, 2nd ed.; Elsevier: New York, 1984, p 450.
22. McMillin, D. R.; McNett, K. M. Chem. Rev. 1998, 98, 1201-1220.
23. Nour, A. G.; Mansour, A. M.; Maha, F. A. E.; Ola, M. E.; Hashem, S. Inorg. Chim. Acta 2015, 435, 187-193.
24. Belal, A. A. M.; El-Deen, I. M.; Farid, N. Y.; Zakaria, R.; Refat, M. S. Spectrochim. Acta A: Mol. Biomol. Spectrosc.
2015, 149, 771-787.
25. Kamatchi, T. S.; Chitrapriya, N.; Kim, S. K.; Fronczek, F. R.; Natarajan, K. Eur. J. Med. Chem. 59, 2013,
253-264.
26. Wang, Y.; Yang, Z. Y. Transit. Metal. Chem. 2005, 30, 902-906.
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